Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and Regeneron’s phase 3 clinical trial results announced Friday show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) in children aged 6-11 years with uncontrolled severe atopic dermatitis significantly improved disease signs, symptoms and health-related quality of life.
Edesa Biotech may continue with its clinical investigation of potential treatment for chronic allergic contact dermatitis EB01, a novel sPLA2 inhibitor, after FDA’s approval.
MatriSys Bioscience is waiting to meet with the US FDA to complete preparations for its company-sponsored Phase 2 trial of its anti-atopic dermatitis topical drug candidate, MSB-01, it said Wednesday.
Sanofi’s pivotal Phase 3 test of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents met its primary and key secondary…
Sanofi and Regeneron Pharmaceuticals got European Commission marketing authorization for Dupixent for use in adults with moderate-to-severe atopic dermatitis (AD)…
LEO Pharma has dosed patients in a phase 3 clinical study of its investigational human monoclonal antibody tralokinumab.